A detailed history of Exodus Point Capital Management, LP transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 127,270 shares of AVXL stock, worth $1.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
127,270
Holding current value
$1.42 Million
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$4.11 - $7.04 $523,079 - $895,980
127,270 New
127,270 $723,000
Q3 2023

Nov 09, 2023

SELL
$6.55 - $9.37 $431,631 - $617,464
-65,898 Reduced 86.67%
10,131 $66,000
Q2 2023

Aug 10, 2023

SELL
$7.66 - $9.5 $157,458 - $195,282
-20,556 Reduced 21.28%
76,029 $618,000
Q1 2023

May 11, 2023

SELL
$8.32 - $11.75 $337,226 - $476,251
-40,532 Reduced 29.56%
96,585 $828,000
Q4 2022

Feb 13, 2023

BUY
$7.65 - $14.43 $647,488 - $1.22 Million
84,639 Added 161.28%
137,117 $1.27 Million
Q3 2022

Nov 10, 2022

SELL
$8.9 - $12.86 $1.12 Million - $1.62 Million
-125,635 Reduced 70.54%
52,478 $542,000
Q2 2022

Aug 19, 2022

BUY
$7.31 - $12.84 $1.11 Million - $1.95 Million
152,189 Added 587.06%
178,113 $1.78 Million
Q1 2022

May 13, 2022

BUY
$9.74 - $17.69 $252,499 - $458,595
25,924 New
25,924 $319,000
Q4 2021

Feb 11, 2022

SELL
$16.88 - $23.31 $596,572 - $823,822
-35,342 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$16.82 - $25.75 $594,452 - $910,056
35,342 New
35,342 $634,000
Q2 2021

Aug 16, 2021

SELL
$10.16 - $28.86 $254,071 - $721,702
-25,007 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$5.17 - $16.13 $129,286 - $403,362
25,007 New
25,007 $374,000
Q2 2019

Aug 14, 2019

SELL
$2.75 - $3.7 $44,550 - $59,940
-16,200 Closed
0 $0
Q1 2019

May 15, 2019

BUY
$1.68 - $3.42 $27,216 - $55,404
16,200 New
16,200 $49,000

Others Institutions Holding AVXL

About ANAVEX LIFE SCIENCES CORP.


  • Ticker AVXL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,942,800
  • Market Cap $871M
  • Description
  • Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...
More about AVXL
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.